Tris Pharma recalled three lots of pediatric ibuprofen concentrated oral suspension USP (NSAID) 50 mg per 1.25 mL due to potentially higher concentrations of ibuprofen.[2] It later expanded the recall to a total of six lots manufactured at the plant in Monmouth Junction, New Jersey.[1] These lots contained, in some units, a concentration of ibuprofen up to 10% higher than the specified limit.[1] The product was sold by CVS, Walmart and Family Dollar through one customer, Tris Pharma.[1] The company states that the safety risks and toxicity of ibuprofen only arise at a dose exceeding 700% of the recommended dose, but infants sensitive to adverse effects may be slightly more at risk at a higher concentration.[1] There is a remote possibility of permanent kidney damage associated with NSAIDs in infants.[1] No serious adverse events related to the withdrawal were reported.[1] Retailers should stop distribution of affected lots and consumers should seek medical attention if they suspect problems.[1][2]